BioVentrix, Inc., a specialty medical device company serving cardiothoracic surgeons and their patients with lifesaving heart failure therapies, announced as the appointment of Steven Chartier as President and Co-Chief Executive Officer. Steve has also been named to the Company’s Board of Directors. In this role, he will work with Co-CEO Dave Richmond to complete BioVentrix’s pivotal RELIVE trial involving 90 treated and 45 control patients, recently authorized by the FDA. Upon expected approval, Steve and Dave will expand commercial reach from the 20+ clinical sites to serve cardiothoracic surgeons and their patients globally.
“Steve brings a wealth of executive management and clinical operations experience to BioVentrix,” said David Richmond, Chair of the Board. “He will be instrumental in building a financially successful, patient-focused medical device company, dedicated to saving lives.”
Also Read: Biotricity and B-Secur Launch Comprehensive Cardiac Monitoring Platform
Mr. Chartier is an experienced leader in both large and small start-up medical device organizations. He most recently held the position of Vice President of Regulatory and Quality at Conformal Medical, Inc., a cardiovascular left atrial appendage company. Prior to that, Mr. Chartier was the Chief Operating Officer at BioVentrix. He has also held clinical, regulatory, and operations positions at Sirtex Medical, Anika Therapeutics, and InfraReDx. Mr. Chartier brings a history of operational excellence, regulatory experience, and clinical trial success to the company, including strong relationships with the US Food and Drug Administration and European regulatory agencies. His goal is to build a team to bring the company through its pivotal clinical trial and secure FDA approval for the Revivent system and procedure.
“I have worked with the BioVentrix technology since 2021,” commented Mr. Chartier. “We are excited to start our clinical trial which we have full confidence will lead to approval by the FDA. With both this approval and our current CE Mark, we will be in position to provide this novel technology to a patient population in dire need of new therapies.”
SOURCE: BioVentrix